BIOD reverse split. ZIOP initiates Phase 3 SCLC trial. BPAX plans further LibiGel trials + AVNR PLX news
Biodel Inc. (Nasdaq:BIOD) announced that it will effect a one-for-four reverse split prior to the start of trading on June 12, 2012. The number of authorized shares of common stock will be adjusted to 25m.
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) announced that has initiated its Phase 3 MATISSE study (Multicenter Adaptive Trial Investigating Small cell lung cancer Survival Endpoints), of palifosfamide for the treatment of small cell lung cancer.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced that it plans to initiate two new LibiGel Phase 3 efficacy trials for the treatment of female sexual dysfunction (FSD).It intends to apply for Special Protocol Assessment (SPA). LibiGel was shown to be not effective following the release of Phase 3 data in December 2012. However, the company argues that this was due to a greater than expected placebo response. BioSante also intends to continue the on-going LibiGel Phase 3 cardiovascular and breast cancer safety study as per protocol, with primary analysis of the safety study due in 2H 2012.
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) said that it plans to initiate a Phase 2 study of AVP-923 for the treatment of agitation in patients with Alzheimer’s disease (AD) during 3Q 2012.
Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced that it has received a $25m milestone payment from Pfizer Inc. as part of the companies’ global commercial agreement for ELELYSO (taliglucerase alfa).